Is melatonin safe to take every night?

Short-term use of melatonin is generally considered safe. Evidence on long-term daily use is limited. Melatonin is most useful as a circadian signal (to help shift your sleep timing) rather than as a sedative. Using it nightly as a sleep aid for months or years without medical guidance is not recommended. If you are relying on melatonin nightly to sleep, this suggests a sleep issue that deserves proper evaluation.

Why are sleeping pills not recommended for long-term use?

The risks accumulate with long-term use: tolerance (needing higher doses), physical and psychological dependence, rebound insomnia when stopping, next-day impairment, and in older adults specifically, increased fall risk and possible cognitive effects. More importantly, they do not address the underlying reasons for insomnia. CBT-I treats the root cause and produces durable improvements — unlike medications, which stop working when you stop taking them.

How do I stop taking sleeping pills after using them for years?

Never stop abruptly — this can cause severe rebound insomnia and, with benzodiazepines, withdrawal symptoms including seizures. Work with your prescribing doctor on a slow taper. The taper can take weeks to months depending on the medication and dose. Starting CBT-I concurrently with tapering dramatically improves success rates and reduces rebound insomnia, and is the recommended evidence-based approach.

Are newer sleep medications like Belsomra safer than older ones?

Orexin receptor antagonists (suvorexant, lemborexant) have a mechanistically different and in some ways more targeted action than Z-drugs, with lower dependence potential and no significant respiratory depression. They are a meaningful improvement for appropriate patients. However, they still carry risks of next-day sedation and are not appropriate for everyone. No sleep medication is entirely without risk, and CBT-I remains the preferred long-term treatment for chronic insomnia.

Sleep Medications: Benefits, Risks, and How to Use Them Wisely

Sleep medications occupy a nuanced space in the management of sleep disorders. For short-term insomnia during acute stress or medical crisis, they can provide genuine relief. For chronic insomnia, they are rarely the right long-term answer — but understanding what each type does, how it works, and what risks it carries allows for informed decisions between patients and their doctors.

The Role of Sleep Medications

The most important principle to understand about sleep medications is that they are symptomatic treatments, not cures. They alter neurological signalling to promote drowsiness or suppress arousal, but they do not fix the underlying cause of insomnia — whether that is anxiety, hyperarousal, poor sleep habits, or an untreated sleep disorder.

For this reason, every major clinical guideline — including those of the American College of Physicians, the American Academy of Sleep Medicine, and the UK's National Institute for Health and Care Excellence (NICE) — recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia, above all medications. Sleep medications are best used as a short-term bridging strategy, or in combination with CBT-I.

That said, sleep medications do have a legitimate role — particularly for acute insomnia, in situations where CBT-I is not immediately accessible, or in clinical situations where rapid symptom relief is genuinely important for health.

Prescription Medications: Classes and Mechanisms

Non-Benzodiazepine Hypnotics ("Z-drugs")

Zolpidem (Ambien/Stilnoct), zopiclone (Zimovane), eszopiclone (Lunesta), and zaleplon (Sonata) are the most widely prescribed sleep medications in many countries. They work by binding to GABA-A receptors in the brain — the same receptors targeted by benzodiazepines — enhancing the effect of GABA, the main inhibitory neurotransmitter, producing sedation.

Z-drugs are effective at reducing sleep onset latency and improving subjective sleep quality in the short term. However, they carry significant risks:

Tolerance: The brain adapts to their effect, requiring progressively higher doses for the same benefit over weeks to months
Dependence: Physical and psychological dependence can develop, making discontinuation difficult
Rebound insomnia: Stopping Z-drugs after regular use causes short-term worsening of insomnia, which traps patients in a cycle of continued use
Next-day sedation and cognitive impairment: Particularly relevant for older adults, in whom zolpidem is associated with significantly elevated fall risk and some evidence of accelerated cognitive decline
Complex sleep behaviours: FDA black box warnings exist for "sleep-driving," sleep-eating, and other complex behaviours with no memory of the event, particularly at higher doses

Z-drugs are generally prescribed for short-term use (2–4 weeks) only. Long-term use is not recommended but is unfortunately common.

Benzodiazepines

Older anxiolytic-hypnotic drugs — including temazepam, nitrazepam, and triazolam — work via the same GABA-A mechanism as Z-drugs but are generally less sleep-specific. They are now second-line options due to their higher risk of dependence, tolerance, rebound phenomena, and daytime sedation. Long-term benzodiazepine use is associated with fall risk in older adults and cognitive impairment.

Orexin Receptor Antagonists

A newer and mechanistically distinct class: suvorexant (Belsomra) and lemborexant (Dayvigo) block orexin (hypocretin) receptors. Orexin is a wakefulness-promoting neuropeptide; blocking its action allows sleep to occur more naturally, rather than imposing sedation. These drugs do not act on GABA receptors, have lower dependence potential than Z-drugs, and carry a lower risk of respiratory depression. They are approved for sleep-onset and sleep-maintenance insomnia. Side effects include next-day drowsiness and rarely sleep paralysis.

Low-Dose Antidepressants

Several antidepressants have sedating properties at low doses that are used off-label for insomnia:

Trazodone (5-HT2 antagonist/reuptake inhibitor): Widely used off-label for insomnia. Low dependence potential, inexpensive. Risks include next-day grogginess, orthostatic hypotension, and in rare cases priapism in men.
Mirtazapine: Strongly sedating, promotes appetite and weight gain. Often used when insomnia co-occurs with depression or poor appetite.
Low-dose doxepin (Silenor): FDA-approved for sleep maintenance insomnia specifically. Works by blocking histamine H1 receptors at very low doses. Good evidence for sleep maintenance without significant next-day effects at therapeutic doses.
Amitriptyline: Older tricyclic antidepressant. Effective for insomnia but significant side effects (dry mouth, constipation, urinary retention, cardiac effects). Particularly problematic in older adults.

Melatonin Agonists

Ramelteon (Rozerem) is a melatonin MT1/MT2 receptor agonist approved for sleep-onset insomnia. It has no dependence potential and no psychomotor impairment, making it suitable for longer-term use and for older patients. It is more effective for circadian rhythm-related insomnia than for primary insomnia, and its sleep-onset improvement is modest compared to Z-drugs.

Prolonged-release melatonin (Circadin, prescription-only in the UK for over-55s) is also used for sleep onset in older adults and has a good safety profile.

Over-the-Counter Sleep Aids

Antihistamine-Based Sleep Aids

Most OTC sleep aids — including products containing diphenhydramine (Nytol, ZzzQuil, Benadryl) or doxylamine (Unisom SleepTabs) — work by blocking histamine H1 receptors in the brain, producing sedation. While they work for occasional use, they have important limitations:

Rapid tolerance development — many people find them significantly less effective after just 3–5 nights of use
Long half-life (particularly diphenhydramine, which has a half-life of 8–12 hours), causing significant next-day grogginess and impairment
Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision) — particularly problematic in older adults, where anticholinergic medications are associated with increased dementia risk with long-term use

These products are appropriate for occasional use (a few nights during a hotel stay, travel, or acute stress) but are not appropriate for chronic insomnia.

Melatonin Supplements (OTC)

Widely available and perceived as "natural," melatonin supplements are often the first thing people try for sleep problems. They are most effective for circadian rhythm disruption — jet lag, shift work, delayed sleep phase — where the timing rather than quality of sleep is the problem.

For primary insomnia (difficulty falling or staying asleep at a consistent time), the evidence for melatonin is weaker than for prescription alternatives. Effective doses are typically much lower than what is sold (0.5–3mg is physiologically active; 10mg tablets provide far more than necessary and may impair next-day alertness). Melatonin taken at the wrong time can shift the circadian clock in an undesired direction.

When to Speak With a Doctor

Never combine sleep medications (prescription or OTC) with alcohol. Both are CNS depressants — the combination can cause dangerously slow breathing, especially in people with underlying respiratory conditions. Always tell your doctor about all sleep aids you are taking, including OTC and supplements, as interactions with other medications can be clinically significant.

Special Considerations: Older Adults

Sleep medication risks are substantially elevated in adults over 65. The American Geriatrics Society's Beers Criteria explicitly identifies benzodiazepines, Z-drugs, and sedating antihistamines as "potentially inappropriate" for older adults due to significantly elevated fall, fracture, and cognitive impairment risk. Non-pharmacological interventions (CBT-I) and medications with safer profiles (low-dose doxepin, melatonin, ramelteon) should be preferred.

Discontinuing Sleep Medications Safely

Long-term users of benzodiazepines and Z-drugs should not stop abruptly — withdrawal can cause rebound insomnia, anxiety, and in severe cases, seizures. A gradual taper under medical supervision is required. The rate of taper depends on the specific drug, dose, and duration of use. Implementing CBT-I concurrently with tapering significantly improves success rates and reduces rebound insomnia severity.

References

Qaseem A, et al. Management of chronic insomnia disorder in adults. Annals of Internal Medicine. 2016;165(2):125–133.
Sateia MJ, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. Journal of Clinical Sleep Medicine. 2017;13(2):307–349.
Fick DM, et al. American Geriatrics Society 2023 updated Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023.
National Institute for Health and Care Excellence (NICE). Hypnotics: Prescribing of hypnotics. 2015.